Tin tức & Cập nhật

In patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy, neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab elicits improvements in event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rate relative to neoadjuvant gemcitabine plus cisplatin, according to the phase III KEYNOTE-B15 study.

Sequential transarterial chemoembolization, stereotactic body radiotherapy, and immunotherapy (START-FIT) using the STRIDE regimen of single-dose tremelimumab plus regular-interval durvalumab offers promising efficacy and is well tolerated in patients with locally advanced, unresectable hepatocellular carcinoma (HCC), a single-arm, multicentre, phase II study in Hong Kong has shown.